Gravar-mail: TB-22 IMMUNOLOGIC PROFILING OF PEDIATRIC BRAIN TUMORS SUGGESTS POTENTIAL BIOMARKERS FOR OPTIMAL IMMUNOTHERAPEUTIC TRIAL SELECTION